Early research suggests size-based sorting of circulating tumor cells may open new avenues for blood-based PD-L1 expression analysis in SCLC patients.
High tumor-specific mRNA levels were associated with increased risk of disease progression in 6,590 patient tumors across 15 cancer types.
Not just a "black box," Picture Health's AI image analysis tool will provide a library of features that elucidate the underlying biology of the cancer.
Single-cell transcriptional and phenotypic profiling of CAR T cells in patients who ultimately relapsed revealed high levels of immune checkpoint receptor TIGIT.
While ALRN-6924 is first being tested in breast and lung cancer, the firm believes it can help patients with any type of p53-mutated cancer avoid chemo toxicities.
The firm's next move will be to pit aumolertinib against AstraZeneca's Tagrisso, the new standard of care in EGFR-mutated NSCLC.
The firm believes its micro-organosphere technology could guide treatment selection for more cancer patients than is currently possible with genomic testing.
A study by UCSF researchers has shown the benefits of offering all brain cancer patients the chance to get genomic sequencing.
It remains to be seen how precision oncology drug and genetic test developers will improve representation of racial and ethnic minorities based on the agency's guidelines.
Cedars-Sinai researchers developing the AI image analysis envision using it on patients already receiving abdominal scans and on those with risk factors.